No abstract available
Keywords:
MEK inhibition; novel therapies; relapsed/refractory DLBCL; selumetinib.
Publication types
-
Clinical Trial, Phase II
-
Letter
-
Multicenter Study
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Benzimidazoles / administration & dosage*
-
Benzimidazoles / adverse effects
-
Chicago
-
Disease-Free Survival
-
Female
-
Humans
-
Lymphoma, Large B-Cell, Diffuse / drug therapy*
-
Lymphoma, Large B-Cell, Diffuse / mortality*
-
Lymphoma, Large B-Cell, Diffuse / pathology
-
Male
-
Middle Aged
-
Survival Rate